Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Cancer Medicine · 2024
DOI: 10.1002/cam4.7317 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jasmine S Sukumar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Premenopause, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Background
The optimal adjuvant endocrine therapy (ET) in hormone receptor positive (HR+) and human epidermal growth factor receptor 2 positive (HER2+) premenopausal breast cancer (BC) remains unclear. Moreover, the benefit and clinical indications of ovarian suppression (OS) is poorly elucidated. We described real‐world patterns surrounding choice of ET and clinicopathologic features which predicted treatment with OS in a contemporary cohort of premenopausal women with HR+/HER2+ BC.
Methods
This retrospective analysis included premenopausal patients with nonmetastatic HR+/HER2+ BC from the CancerLinQ Discovery database from January 2010 to May 2020. Women were less than 50 years and received chemotherapy, anti‐HER2 therapy, and ET. They were categorized into 1 of 4 groups based on type of ET prescribed at initiation: aromatase inhibitor (AI) + OS, OS, tamoxifen + OS, or tamoxifen. Multivariable logistic regression assessed associations between clinicopathologic features and OS use.
Results
Out of 360,540 patients with BC, 937 were included. The majority ( n = 818, 87%) were prescribed tamoxifen, whereas 4 (0.4%), 50 (5.3%), and 65 (6.9%) received OS, tamoxifen + OS and AI + OS, respectively. No clinicopathologic features predicted OS use apart from age; patients
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
- The Ohio State University, College of Public Health, Columbus, Ohio, USA.
- Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
- Yale Cancer Center, New Haven, Connecticut, USA.
ORCID-Profile: Jasmine S Sukumar, Dionisia Quiroga, Daniel G Stover
Förderung
- NCATS NIH HHS
Zitieren
APA
Sukumar, J. S., Sardesai, S., Ni, A., Williams, N., Johnson, K., Quiroga, D., Ramaswamy, B., Wesolowski, R., Cherian, M., Stover, D. G., Gatti-Mays, M., Pariser, A., Sudheendra, P., George, M. A., & Lustberg, M. (2024). Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer. Cancer Medicine. https://doi.org/10.1002/cam4.7317
Vancouver
Sukumar JS, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, et al. Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer. Cancer Medicine. 2024. doi:10.1002/cam4.7317
BibTeX
@article{Sukumar2024,
author = {Sukumar, Jasmine S and Sardesai, Sagar and Ni, Andy and Williams, Nicole and Johnson, Kai and Quiroga, Dionisia and Ramaswamy, Bhuvana and Wesolowski, Robert and Cherian, Mathew and Stover, Daniel G and Gatti-Mays, Margaret and Pariser, Ashley and Sudheendra, Preeti and George, Mridula A and Lustberg, Maryam},
title = {Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7317}
}
EUVIMED